Diabetic Macular Edema News and Research

RSS

Fluid can leak into the center of the macula, the part of the eye where sharp, straight-ahead vision occurs. The fluid makes the macula swell, blurring vision. This condition is called macular edema. It can occur at any stage of diabetic retinopathy, although it is more likely to occur as the disease progresses. About half of the people with proliferative retinopathy also have macular edema.

Quark Pharmaceuticals' QPI-1002 receives orphan drug designation from FDA

Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, announced today that the US FDA has granted orphan drug designation for QPI-1002 (also referred to as "I5NP"), a synthetic siRNA targeting p53 mRNA for the prophylaxis of delayed graft function (DGF) in kidney transplant patients.

17 Feb 2010

pSivida reports consolidated net loss of $24,000 for quarter ended December 31, 2009

pSivida Corp. , a drug delivery company with two of the only three ophthalmic sustained release delivery products approved by the FDA for treatment of back-of-the-eye diseases, today announced financial results for its second quarter and six months ended December 31, 2009.

12 Feb 2010

Lux Biosciences seeks US and European marketing approval for LUVENIQ

Lux Biosciences, Inc. today announced its submission of simultaneous regulatory filings to both the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) seeking marketing approval for its investigational drug LUVENIQ™ (LX211; oral voclosporin) for the treatment of noninfectious uveitis involving the intermediate or posterior segments of the eye.

5 Feb 2010

6th Annual Diabetes Conference to feature ocular drug delivery in diabetic retinopathy

pSivida Corp., a leader in the development of tiny, sustained-release drug delivery technologies, with two of the only three ophthalmic sustained-release delivery products approved by the FDA for treatment of back of the eye diseases, announced that its chief executive officer, Dr. Paul Ashton, will discuss ocular drug delivery in diabetic retinopathy during a presentation at the 6th Annual Diabetes Conference in London, on Friday, January 22.

21 Jan 2010

DSMB recommends Quark Pharmaceuticals to continue clinical study of QPI-1002

Quark Pharmaceuticals, Inc., the world leader in clinical development of RNAi-based therapeutics, announced today that the independent Data Safety Monitoring Board ("DSMB") recommended that QPI-1002 (I5NP) continue on to the next phase of clinical testing.

5 Jan 2010

iCo Therapeutics grants 725,000 stock options to directors, officers and employees

iCo Therapeutics Inc. - iCo Therapeutics (the "Company") announced today that on December 29, 2009 the Company granted a total of 725,000 stock options to directors, officers and employees of the Company.

31 Dec 2009

Steroids not superior to laser treatments for DME

Researchers led by specialists at the Johns Hopkins Wilmer Eye Institute have found that injecting a corticosteroid, triamcinolone, directly into the eye may slow the progression of proliferative diabetic retinopathy, a complication of diabetes that frequently leads to blindness.

27 Dec 2009

Positive results from Alimera Sciences' Iluvien FAME trial for DME

Alimera Sciences, Inc., a privately held biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today reported top-line results from the month 24 readout of the FAME Study.

23 Dec 2009

Phase 1 clinical trial of iCo-007 demonstrates positive safety profile

iCo Therapeutics Inc. - iCo Therapeutics ("iCo") is pleased to announce that its Phase 1 clinical trial of iCo-007, having enrolled all patients in four cohorts of increasing concentration (110ug, 350ug, 700ug, 1000ug), has to date demonstrated a positive safety profile.

12 Dec 2009

iCo Therapeutics to present an overview of its iCo-007 VEGF "+" agent at the ISOPT conference

iCo Therapeutics Inc. is pleased to announce that an overview of iCo-007, entitled "iCo-007 a VEGF "+" Agent for the Potential Treatment of Diabetic Macular Edema and Diabetic Retinopathy" will be presented at the 8th International Symposium on Ocular Pharmacology and Therapeutics ("ISOPT"), a major international ocular conference.

3 Dec 2009

Burrill Biotech Select Index manages to claw back almost half the value it lost in October

The Burrill Biotech Select Index managed to claw back almost half the value it lost in October. The Select's gain of 4.5 percent mirrored what was also an excellent month for the general markets with the Dow up 6.5 percent and the NASDAQ up 4.8 percent in value.

2 Dec 2009

iCo Therapeutics reports financial results for three months ended September 30, 2009

iCo Therapeutics Inc. today reported financial results for the three months ended September 30, 2009. Amounts, unless specified otherwise, are expressed in Canadian dollars and in accordance with Canadian Generally Accepted Accounting Principles (Canadian GAAP).

27 Nov 2009

ThromboGenics issues business update for the third-quarter of 2009

ThromboGenics NV, a biopharmaceutical company focused on innovative medicines for eye disease, vascular disease and cancer, is today issuing a business update for the period ending 30 September, 2009.

4 Nov 2009

Multicenter study finds AMD patients can benefit from cataract surgery

This month's Ophthalmology, the journal of the American Academy of Ophthalmology (Academy) reports on a national study that finds cataract surgery is likely to benefit patients with age-related macular degeneration (AMD) at all stages of the disease, on a clinical trial showing that the steroid triamcinolone may be effective in advanced diabetic macular edema (DME) patients when standard treatment fails, and on the public's use of two Academy-sponsored online eye health forums.

2 Nov 2009

iCo Therapeutics announces $4,000,000 brokered private placement

iCo Therapeutics Inc. (the "Company") is pleased to announce that further to its press release issued October 20, 2009 announcing a $4,000,000 brokered private placement (the "Offering") co-led by Loewen, Ondaatje, McCutcheon Limited and Versant Partners Inc. (collectively, the "Agents"), the Company has completed the first tranche of the Offering through the issuance of 6,000,000 common shares of Company (the "Shares"). The Shares were issued at a price of $0.48 per share for gross proceeds of $2,880,000.

31 Oct 2009

Isotechnika Pharma reports voclosporin Phase 2/3 clinical trial results at the AAO meeting

Isotechnika Pharma Inc. today announced that results of the international Phase 2/3 clinical trials studying voclosporin, conducted by its partner Lux Biosciences, were the subject of two podium presentations at the American Association of Ophthalmology (AAO) meeting and of a presentation at the satellite meeting of the American Uveitis Society (AUS) in San Francisco, October 24-27.

27 Oct 2009

Quark Pharmaceuticals receives a Japanese patent for its hypoxia regulated genes

Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced issuance of Japanese Patent Number: 4354633, titled, "Hypoxia regulated genes," on August 7, 2009.

27 Oct 2009

LX211 may become the first approved oral treatment for modifying the course of uveitis

An experimental drug, LX211 (LUVENIQ - oral voclosporin), may become the first approved oral treatment capable of modifying the course of uveitis, a group of serious eye conditions inevitably associated with either severe vision loss or substantial morbidity from steroid use.

27 Oct 2009

FDA grants Fast Track designation for MacuSight's Perceiva

MacuSight, a developer of innovative therapeutics for the treatment of severe ocular diseases and conditions, today announced that it has received Fast Track designation from the United States Food and Drug Administration (FDA) for Perceiva, the company's proprietary ocular sirolimus product, for the treatment of diabetic macular edema (DME).

21 Oct 2009

pSivida achieves milestone in Phase III Iluvien trial, last patient completes two-year follow up visit

pSivida Corp., a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today announced that the last patient in the Phase III clinical trial being conducted by its collaborative partner, Alimera Sciences, for a new treatment for diabetic macular edema (DME) has completed the two-year follow up visit.

15 Oct 2009

Diabetic Macular Edema News and Research

Quark Pharmaceuticals' QPI-1002 receives orphan drug designation from FDA

pSivida reports consolidated net loss of $24,000 for quarter ended December 31, 2009

Lux Biosciences seeks US and European marketing approval for LUVENIQ

6th Annual Diabetes Conference to feature ocular drug delivery in diabetic retinopathy

DSMB recommends Quark Pharmaceuticals to continue clinical study of QPI-1002

iCo Therapeutics grants 725,000 stock options to directors, officers and employees

Steroids not superior to laser treatments for DME

Positive results from Alimera Sciences' Iluvien FAME trial for DME

Phase 1 clinical trial of iCo-007 demonstrates positive safety profile

iCo Therapeutics to present an overview of its iCo-007 VEGF "+" agent at the ISOPT conference

Burrill Biotech Select Index manages to claw back almost half the value it lost in October

iCo Therapeutics reports financial results for three months ended September 30, 2009

ThromboGenics issues business update for the third-quarter of 2009

Multicenter study finds AMD patients can benefit from cataract surgery

iCo Therapeutics announces $4,000,000 brokered private placement

Isotechnika Pharma reports voclosporin Phase 2/3 clinical trial results at the AAO meeting

Quark Pharmaceuticals receives a Japanese patent for its hypoxia regulated genes

LX211 may become the first approved oral treatment for modifying the course of uveitis

FDA grants Fast Track designation for MacuSight's Perceiva

pSivida achieves milestone in Phase III Iluvien trial, last patient completes two-year follow up visit

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News